Optimi Health Corp. (Nasdaq: OPTH; CSE: OPTI) plans to begin a Health Canada-authorized Phase 3 clinical trial evaluating MDMA-assisted therapy for post-traumatic stress disorder in 2027.
According to the company’s September 16 announcement, the multicenter Canadian study is expected to enroll up to 100 veterans and current or former frontline workers. Eligible groups will include military personnel, police officers, paramedics, firefighters and healthcare workers.
Participants will receive Optimi’s synthetic MDMA hydrochloride during two supervised sessions combining the drug with psychotherapy. The sessions will take place several weeks apart, followed by post-treatment evaluations. The primary efficacy endpoint will measure changes in PTSD severity using the Clinician-Administered PTSD Scale, known as CAPS-5.
Optimi’s announcement did not identify the trial sites, exact MDMA doses, comparison group, masking method or expected completion date. Those details will be important for assessing the study’s ability to produce evidence suitable for a future regulatory submission.
CEO and co-founder Dane Stevens said Optimi is “preparing to advance our synthetic MDMA” with the goal of eventually seeking registration. The company also has a Health Canada-authorized Phase 2 study planned for its natural psilocybin product in major depressive disorder.
Authorization to conduct the trial does not constitute approval of MDMA-assisted therapy. Optimi said the treatment’s safety and efficacy remain under investigation and that none of its MDMA products has received market authorization from Health Canada. The company currently supplies MDMA to authorized prescribers in Australia and through regulated access pathways in Canada.
The broader regulatory history also warrants caution. In 2024, the U.S. FDA declined to approve an MDMA-assisted treatment developed by another sponsor after raising concerns about the supporting evidence and requesting an additional late-stage study. Optimi’s Canadian program will therefore develop against a backdrop of heightened scrutiny concerning trial design, safety monitoring and the role of psychotherapy.
Financially, Optimi reported C$13.1 million in cash as of June 30, 2026, following a public offering that generated C$20.7 million in gross proceeds. For the nine-month period, it recorded C$239,700 in revenue and a net loss of approximately C$5.55 million.
In August, Optimi established a discretionary equity facility allowing it to sell up to US$100 million in common shares over time, subject to contractual conditions. The facility provides potential access to capital, but share sales or conversion of the associated commitment notes could dilute existing shareholders.
Upcoming Catalysts
- Disclosure of the complete Phase 3 protocol and trial sites
- Trial initiation and first-patient dosing, expected in 2027
- Enrollment updates for veterans and frontline workers
- Progress in Optimi’s separate Phase 2 psilocybin study
- Details regarding regulatory strategy and expected data timing
- Financing activity under the company’s equity facility
Sources
- Optimi Health Phase 3 MDMA trial announcement — September 16, 2026
- Optimi Health Form 6-K — SEC, September 16, 2026
- Optimi Health interim financial statements for the period ended June 30, 2026
- Optimi Health discretionary equity facility announcement — August 14, 2026
- U.S. FDA declines prior MDMA-assisted PTSD application — Reuters, August 9, 2024
Editorial Disclosure
This article is based entirely on publicly available information including company announcements, SEC and Canadian securities filings, and publicly available news sources. Securities discussed or referenced include Optimi Health Corp. (Nasdaq: OPTH; CSE: OPTI; FSE: 8BN). Biotech Stocks Daily has not received compensation from Optimi Health, its management, investor relations representatives or any third party for this specific article. Biotech Stocks Daily may have current or past paid business relationships with other companies, which do not influence the content or conclusions of this article. No staff member or principal of Biotech Stocks Daily holds a position in any security mentioned at the time of publication.
Sources used include Optimi Health’s September 16, 2026 clinical-trial announcement and SEC Form 6-K, its financial statements for the nine-month period ended June 30, 2026, its August 14, 2026 equity-facility announcement and publicly available reporting concerning the regulatory history of MDMA-assisted therapy. Information about the planned trial originated primarily from Optimi and has not been independently validated by Biotech Stocks Daily.
The planned Phase 3 trial has not begun. Health Canada’s authorization to conduct a clinical trial does not constitute approval of Optimi’s MDMA products or establish that MDMA-assisted therapy is safe or effective. The September 16 announcement did not identify the trial sites, precise doses, comparison group, masking method or expected completion date. Trial design, enrollment and timing may change, and study results may not support a future marketing application.
Optimi’s access to regulated supply programs in Australia and Canada should not be interpreted as general marketing authorization. MDMA-assisted therapy faces clinical, ethical and regulatory scrutiny, and another sponsor’s U.S. application was previously declined. Outcomes involving other MDMA products or protocols do not establish how Optimi’s planned study will perform.
Financial information is reported in Canadian dollars unless otherwise noted and reflects the company’s position as of June 30, 2026. Optimi reported limited revenue, continuing operating losses and reliance on financing. Its discretionary equity facility may provide capital but could result in substantial shareholder dilution if common shares are sold or commitment notes are converted. No real-time securities prices are included.
Biotechnology securities are speculative investments carrying significant risk, including the potential total loss of capital. Coverage on Biotech Stocks Daily is provided for informational and educational purposes only. Biotech Stocks Daily is not a registered investment advisor. Nothing in this article constitutes financial, investment or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making investment decisions. For more information, please see our full DISCLAIMER.
